Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

54.07 +1.52 (+2.89%)

Delayed Quote Updated: 3:59 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

38 39 Next >

KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

January 26, 2024

Via Business Wire

Sarepta Therapeutics Inc.: Why it's a rising gene therapy star

January 23, 2024

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.

Via MarketBeat

Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe ↗

January 16, 2024

Roche's Tecentriq SC, the EU's first subcutaneous PD-(L)1 immunotherapy, approved for faster, 7-minute injections

Via Benzinga

Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer ↗

January 16, 2024

FDA approves Merck's Keytruda for advanced cervical cancer. Keytruda plus chemoradiotherapy shows a 41% improvement in progression-free survival.

Via Benzinga

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗

January 12, 2024

The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.

Via Investor's Business Daily

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

Via Investor Brand Network

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END

Via FinancialNewsMedia

Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference ↗

January 10, 2024

Cramer shared his insights during his attendance at JPMorgan's healthcare conference,

Via Benzinga

Topics Artificial Intelligence

2 Growth Stocks That Could Make You Richer in 2024 and Beyond ↗

January 09, 2024

Last year wasn't great for either stock, but that's no reason to ignore them.

Via The Motley Fool

Why Is LumiraDx (LMDX) Stock Down 13% Today? ↗

January 08, 2024

LumiraDx stock is falling hard on Monday as investors in LMDX prepare for the company's shares to be delisted on Tuesday!

Via InvestorPlace

3 Great Foreign Companies to Invest in Right Now ↗

January 08, 2024

These international companies can bring a helpful new flavor to your investment portfolio.

Via The Motley Fool

Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗

January 07, 2024

Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...

Via Talk Markets

Stocks Commence 2024 Bullish Rally: LMDX, HNRC, BULT, HALB, SPZI

January 05, 2024

Via AB Newswire

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M ↗

January 02, 2024

Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.

Via Benzinga

Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry ↗

December 21, 2023

Which weight-loss stocks are good buys today?

Via The Motley Fool

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗

December 21, 2023

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy...

Via Benzinga

This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know ↗

December 20, 2023

It isn't the first drugmaker to partner with the chipmaker, and it won't be the last.

Via The Motley Fool

Topics Artificial Intelligence

FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results

December 19, 2023

From Genentech

Via Business Wire

Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO ↗

December 15, 2023

Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering.

Via Benzinga

Topics Regulatory Compliance

The 3 Most Undervalued Biotech Stocks to Buy in December ↗

December 15, 2023

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Via InvestorPlace

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

December 14, 2023

From Roivant Sciences

Via GlobeNewswire

Can Altimmune's weight-loss drug be a game-changer?

December 14, 2023

The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold

Via MarketBeat

Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗

December 11, 2023

Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen...

Via Benzinga

New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma

December 10, 2023

From Genentech

Via Business Wire

New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A

December 09, 2023

From Genentech

Via Business Wire

Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

December 08, 2023

From Genentech

Via Business Wire

Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment

December 08, 2023

From Genentech

Via Business Wire

Why Viking Therapeutics Was Crushing It This Week ↗

December 08, 2023

Nowadays, it's good to be a developer of next-generation weight loss drugs.

Via The Motley Fool

JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities ↗

December 06, 2023

Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.